A Phase 2/3, Prospective, Randomized, Multi-center, Open-Label, Controlled Trial to Assess the Efficacy & Safety of Cellular Immunotherapy With MDR-102 for Induction of Immune Quiescence in Recipients of HLA-mismatched, LD Kidney Transplants
Latest Information Update: 10 Jun 2024
At a glance
- Drugs MDR 102 (Primary) ; Immunosuppressants
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Sponsors Medeor Therapeutics
- 05 Jun 2024 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 17 Oct 2023 Planned End Date changed from 1 Oct 2025 to 1 Oct 2026.
- 17 Oct 2023 Planned primary completion date changed from 1 Sep 2025 to 1 Sep 2026.